Johnson & Johnson Innovative Medicine

Johnson & Johnson Innovative Medicine is the pharmaceutical division of Johnson & Johnson and one of the world’s leading innovators in prescription medicines. Formerly known as the Janssen Pharmaceutical Companies of Johnson & Johnson, the business adopted its current global brand identity in 2023 while continuing its long-standing mission of developing science-based therapies for serious diseases. The organization traces its pharmaceutical heritage to Janssen Pharmaceutica, founded by Dr. Paul Janssen, whose pioneering research transformed modern medicine.

Today, Johnson & Johnson Innovative Medicine focuses on discovering and delivering breakthrough treatments across oncology, immunology, neuroscience, pulmonary hypertension, cardiovascular diseases, and specialty ophthalmology. The company combines advanced molecular biology, genomics, cell therapy, data science, and artificial intelligence to accelerate drug development and improve patient outcomes. Its medicines are available in more than 150 countries through an extensive global manufacturing and commercial network.

The company invests billions of dollars annually in research and development while maintaining strategic collaborations with universities, hospitals, biotechnology companies, and healthcare organizations worldwide. It follows rigorous international quality standards, regulatory compliance, and sustainable manufacturing practices across its operations. Through continuous innovation, patient-centered research, and a strong commitment to scientific excellence, Johnson & Johnson Innovative Medicine continues to play a significant role in shaping the future of pharmaceutical healthcare and improving lives around the world.